Log In Sign up
The largest database of trusted experimental protocols

Ivis lumina 2 in vivo imaging system

Manufactured by PerkinElmer
Visit Supplier
Sourced in United States

The IVIS Lumina II In Vivo Imaging System is a high-performance bioluminescence and fluorescence imaging platform designed for preclinical research. The system captures real-time images of biological processes in living subjects, enabling researchers to non-invasively monitor a variety of biological events, such as gene expression, cell trafficking, and tumor growth.

Automatically generated - may contain errors

Lab products found in correlation

Living image software, by PerkinElmer (4 mentions) D luciferin, by Thermo Fisher Scientific (2 mentions) Lipofectamine 2000, by Thermo Fisher Scientific (2 mentions) Psbbi pur, by Addgene (1 mentions) Pcmv cat t7 sb100, by Addgene (1 mentions) Xenolight d luciferin potassium salt, by PerkinElmer (1 mentions) Strain nod cg prkdcscid il2rgtm1wjl szj, by Jackson ImmunoResearch (1 mentions) Living image 4, by PerkinElmer (1 mentions) Rediject d luciferin ultra, by PerkinElmer (1 mentions) Coelenterazine, by GoldBio (1 mentions) Living image software version 4, by PerkinElmer (1 mentions) Plastic dishes, by BD (1 mentions) D luciferin, by PerkinElmer (1 mentions) Female athymic nude mice, by Charles River Laboratories (1 mentions) Gastrosense 750, by PerkinElmer (1 mentions) Luciferin, by PerkinElmer (1 mentions) Female nod scid mice, by Taconic Biosciences (1 mentions) Ack lysing buffer, by Thermo Fisher Scientific (1 mentions) Nsg mice, by Jackson ImmunoResearch (1 mentions) Collagenase 4, by Merck Group (1 mentions)

Close spelling variants of this product

IVIS Lumina in vivo imaging system Lumina In Vivo Imaging System IVIS Lumina II imaging system IVIS Lumina II in IVIS Lumina imaging system IVIS Lumina II system IVIS Lumina system IVIS Lumina II IVIS imaging system IVIS Lumina

32 protocols using ivis lumina 2 in vivo imaging system

1

Bioluminescent Melanoma Tumor Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
The B16-F10 luciferase cell line was generated by stably transfected with luciferase expressing vector pSBbi-pur (Addgene #60523) and pCMV (CAT)T7-SB100 (Addgene #34879) by Lipofectamine 2000 (Thermo Fisher). C57BL/6 (8–12 weeks old) male mice were inoculated with 5 × 105 B16-F10 cells. Twelve days later, mice were injected with engineered macrophages. Four days after macrophage injection, XenoLight D-Luciferin Potassium Salt (PerkinElmer) was intra-peritoneally injected at 10 μL/g of body weight for each mouse. Images were detected by an IVIS Lumina II in vivo imaging system (PerkinElmer, Thermo Fisher, US) 10–15 min after injection.
Dong Y., Zhang S., Gao X., Yin D., Wang T., Li Z., Wan Z., Wei M., Luo Y., Yang G, & Liu L. (2021). HIF1α epigenetically repressed macrophages via CRISPR/Cas9-EZH2 system for enhanced cancer immunotherapy. Bioactive Materials, 6(9), 2870-2880.
+ Open protocol
+ Expand
2

Phototherapy Against Vibrio vulnificus Infection

Check if the same lab product or an alternative is used in the 5 most similar protocols
To assess the efficacy of aBL in the prevention (or post-exposure prophylaxis) of V. vulnificus burn infections in mice, aBL was initiated 30 min after bacterial inoculation. To study the efficacy of aBL in the treatment of infection, aBL was started 6 h after bacterial inoculation, as our preliminary studies showed that a period of 6 h was sufficient to establish V. vulnificus infection in mice (Supplementary Figure 1). The severity of infection in mice was quantified by measuring the intensity of the bioluminescence signal [relative luminescence units (RLU)] from the photon emission by V. vulnificus using an IVIS Lumina II In Vivo Imaging System (PerkinElmer, Waltham, MA). In a subset of mice (n = 2), the correlation between RLU and CFU was determined following exposure to varying aBL intensities of 0, 15, 30, 60, 120, and 360 J/cm2. For both conditions (i.e., prevention or treatment of infection), aBL was delivered with radiant exposures of 0, 30, 60, 90, 120, 150, 180, and 360 J/cm2, reflecting 0, 5, 10, 15, 20, 25, 30, and 60 min of irradiation time (irradiance = 100 mW/cm2), respectively. Bioluminescence imaging was performed after each exposure to light. After aBL treatment, mice were monitored for survival for up to 7 days.
dos Anjos C., Leanse L.G., Liu X., Miranda H.V., Anderson R.R, & Dai T. (2022). Antimicrobial Blue Light for Prevention and Treatment of Highly Invasive Vibrio vulnificus Burn Infection in Mice. Frontiers in Microbiology, 13, 932466.
+ Open protocol
+ Expand
3

Bioluminescence Imaging of Soft Tissue Tumors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Tumours in soft tissue or hind limbs were measured using bioluminescence-based in vivo imaging (IVIS Lumina II in Vivo Imaging System (PerkinElmer, Waltham, MA, USA) and Living Image® 4.5.4 software) 2-, 7-, 15- and 17-days post tumour cell injection, 5 minutes following subcutaneous injection of 6 mg/kg D-Luciferin (Invitrogen, Waltham, MA, USA). Maximum BLI thresholds were set as 5e5 photons, and minimum BLI thresholds were modified across experimental models to allow the visualisation of tumour-derived bioluminescent signals.
Zhou J., Down J.M., George C.N., Murphy J., Lefley D.V., Tulotta C., Alsharif M.A., Leach M, & Ottewell P.D. (2022). Novel Methods of Targeting IL-1 Signalling for the Treatment of Breast Cancer Bone Metastasis. Cancers, 14(19), 4816.
+ Open protocol
+ Expand
4

Subcutaneous and Metastatic Tumor Imaging

Check if the same lab product or an alternative is used in the 5 most similar protocols
All experiments were performed in accordance with the Guidelines for Animal Experiments at West Virginia University and approved by the Institutional Animal Care and Use Committee. Immunodeficient NOD/SCID gamma mice (NSG), strain NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (Jackson Laboratory), were injected with 1 × 106 of luciferase-labeled cells subcutaneously or via the tail vein. Tumor growth was monitored weekly using IVIS Lumina II in Vivo Imaging system (PerkinElmer), and an external caliper (VWR International) was used for the subcutaneous model. Tumor volume was calculated using the formula: tumor volume [mm3] = 1/2 (length [mm]) × (width [mm]2). At the end of the experiments mice were euthanized, and their organs were removed and imaged ex vivo on a Petri dish to evaluate metastasis. Bioluminescent images were quantified using the Living Image software (PerkinElmer). Tissue processing and H&E staining was carried out by the WVU Pathology Laboratory for Translational Medicine using standard procedures.
Voronkova M.A., Luanpitpong S., Rojanasakul L.W., Castranova V., Dinu C.Z., Riedel H, & Rojanasakul Y. (2017). SOX9 Regulates Cancer Stem-Like Properties and Metastatic Potential of Single-Walled Carbon Nanotube-Exposed Cells. Scientific Reports, 7, 11653.
+ Open protocol
+ Expand
5

Xenograft and Metastasis Models of Prostate Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols
A total of 26 male BALB/c nude mice (8 weeks, 20–22 g) were used in present study. To establish subcutaneous xenograft tumor model, 2 × 106 PC-3 cells were injected on sides of the flank of mice (n = 8 per group). 28 days after injection, the mice were sacrificed the size and the weight of tumors were measured. To establish pulmonary metastasis model, 2 × 106 PC-3 cells were inoculated via caudal vein (n = 10 per group). After 28 days, the fluorescent signal of pulmonary metastases was detected and analyzed using an IVIS Lumina II In Vivo Imaging System (Perkin Elmer) with Live Imaging Acquisition and Analysis software. Then the lungs of mice were removed and HE staining was performed to check the number of metastatic nodules. All the protocols of animal experiments have been approved by the Animal Care Committee of Fujian Medical University.
Chen Y.H., Chen H., Lin T.T., Zhu J.M., Chen J.Y., Dong R.N., Chen S.H., Lin F., Ke Z.B., Huang J.B., Wei Y., Zheng Q.S., Xue X.Y, & Xu N. (2023). ARPC1A correlates with poor prognosis in prostate cancer and is up-regulated by glutamine metabolism to promote tumor cell migration, invasion and cytoskeletal changes. Cell & Bioscience, 13, 38.
+ Open protocol
+ Expand
6

Luciferase Assay for Wnt Signaling Analysis

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Stable cell lines expressing the TOP-FLASH reporter were generated by transducing
cells with 7TFP recombinant lentiviruses (Fuerer
and Nusse, 2010), and luciferase assay was performed as previously
described (Singh et al., 2012 (link)). Briefly,
Rediject D-Luciferin Ultra (Perkin Elmer) was added in 0.2 ml fresh media
(1–200 dilution) to each well of cells in a 96-well plate and incubated for 15
min at 37°C. Luciferase activity was imaged with the IVIS Lumina II In Vivo
Imaging System (Perkin Elmer). The radiance of each well was determined using Living
Image 4.2 software (Perkin Elmer), background corrected by subtracting the mean
signal from empty wells and normalized both to the relative cell number of each well
as determined by Syto60 assay and the resulting normalized mean value of untreated
wells.
Rothenberg S.M., Concannon K., Cullen S., Boulay G., Turke A.B., Faber A.C., Lockerman E.L., Rivera M.N., Engelman J.A., Maheswaran S, & Haber D.A. (2015). Inhibition of mutant EGFR in lung cancer cells triggers SOX2-FOXO6-dependent survival pathways. eLife, 4, e06132.
+ Open protocol
+ Expand
7

Bioluminescence Imaging of Candida albicans in Wound

Check if the same lab product or an alternative is used in the 5 most similar protocols
The bioluminescence imaging of C. albicans in mouse abrasion wounds was performed by using an IVIS Lumina II In Vivo Imaging System (PerkinElmer, Inc, Hopkinton, MA). Prior to imaging (before and during treatment), 20 μL of coelenterazine (500 mg/mL; Gold Biotechnology, Inc., St. Louis, MO) was topically applied to the infected wounds, as described previously [14 (link)]. Following each aliquot of aBL, the wounds containing the bioluminescent C. albicans were then imaged for their relative luminescence as an indicator for cell viability, which was found previously to correlate with the CFU [14 (link)]. The system was operated using the Living Image software, which provides image acquisition tools including photon counting to permit real-time quantification of the relative luminescence units (RLU).
Leanse L.G., Goh X.S, & Dai T. (2019). Quinine Improves the Fungicidal Effects of Antimicrobial Blue Light: Implications for the Treatment of Cutaneous Candidiasis. Lasers in surgery and medicine, 52(6), 569-575.
+ Open protocol
+ Expand
8

Bioluminescence Imaging of Tumor Burden

Check if the same lab product or an alternative is used in the 5 most similar protocols
2F7-BR44 distribution in the animals was monitored weekly after tumor challenge by bioluminescence imaging using an IVIS Lumina II In Vivo Imaging System (PerkinElmer, Waltham, MA, USA). PierceTM D-luciferin (4.5 mg; Thermo Fisher Scientific) was injected s.c. in the abdominal area and imaging performed after 5–10 min under isoflurane anesthesia. Tumor burden was quantified as the total photon flux per second within the region of interest (whole body of the mouse) using the Living Image® Software, Version 4.7.3 (PerkinElmer). All regions of interest were identical in size, and sensitivity settings were adjusted to maintain the same counts per pixel (200–800 for Week 1 images and 10,000–30,000 for Week 3 images in the local tumor model; 2000–12,000 for the disseminated model). Imaging was performed in the UCLA Crump Preclinical Imaging Technology Center.
Daniels-Wells T.R., Candelaria P.V., Kranz E., Wen J., Wang L., Kamata M., Almagro J.C., Martínez-Maza O, & Penichet M.L. (2023). Efficacy of Antibodies Targeting TfR1 in Xenograft Mouse Models of AIDS-Related Non-Hodgkin Lymphoma. Cancers, 15(6), 1816.
+ Open protocol
+ Expand
9

Bioluminescence Imaging: In Vitro, Ex Vivo, and In Vivo

Check if the same lab product or an alternative is used in the 5 most similar protocols
In vitro (cells in culture), ex vivo (harvested organs and tissues), and in vivo (living mouse) bioluminescence analysis was performed using the IVIS Lumina II in vivo imaging system (PerkinElmer, Waltham, MA, USA) as previously described.[16 (link)] For in vitro analysis, HCT 116 cells were cultured on plastic dishes (BD, Franklin Lakes, NJ, USA), then incubated with media in the presence of D-luciferin (PerkinElmer) (150 μg/ml) for 5 min, and then analyzed. The procedure was similar for bioptic samples: Tissues were washed in phosphate-buffered saline (PBS), incubated for 5 min in the presence of D-luciferin (150 μg/ml) dissolved in PBS, and then analyzed. For in vivo analysis, animals were anesthetized by intraperitoneal injection of avertin (200 mg/kg). Luciferin dissolved in PBS (150 mg/kg) was also administered intraperitoneally. After 10 min, the animal was put into the detection system, and the signal was acquired in a time range of 1–5 min, depending on signal intensity. Living Image Software (PerkinElmer, Waltham, MA, USA) was used to analyze the signals in manually selected regions of interest. Data were expressed as photons per second per square centimeter per steradian (p/s/cm2/sr).
Magistri P., Battistelli C., Toietta G., Strippoli R., Sagnotta A., Forgione A., Di Benedetto F., Uccini S., Vittorioso P., D’Angelo F., Aurello P., Ramacciato G, & Nigri G. (2019). In vivo Bioluminescence-Based Monitoring of Liver Metastases from Colorectal Cancer: An Experimental Model. Journal of Microscopy and Ultrastructure, 7(3), 136-140.
+ Open protocol
+ Expand
10

Biodistribution of Labelled ZPDC 3 in Pancreatic Tumor Xenografts

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal procedures were performed in accordance with Animal Welfare Regulations (CFR, Title 9, Chapter 1, Subchapter A, Parts 1, 2 and 3) and the Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee (IACUC) at University at Buffalo. The biodistribution of ZPDC 3 was investigated in human pancreatic tumor xenograft model. MIA PaCa-2 cells (5 × 106 cells) were subcutaneously injected at the right flanks of female athymic nude mice (6-week old, Charles River Laboratories). Tumor volume was calculated by the equation V = (L×W2)/2. When the tumor volume reached 100 mm3, the mice were injected with PBS control, Cy5.5-N3 and Cy5.5-labelled ZPDC 3 by mouse tail vein at Cy5.5 dose of 1.5 mg/kg of body weight. Whole body fluorescence images before and at 5 min, 1 h, 4 h, 24 h after injection were taken by IVIS Lumina II in vivo imaging system (PerkinElmer, Waltham, MA). At 24 h after injection, mice were sacrificed to collect tumors and major organs (including brain, heart, liver, spleen, lung and kidney). The fluorescence signals of Cy5.5 in tumors and major organs were measured by the IVIS Lumina II in vivo imaging system to determine the biodistribution of ZPDC 3.
Sun H., Yan L., Zhang R., Lovell J.F., Wu Y, & Cheng C. (2021). A Sulfobetaine Zwitterionic Polymer-Drug Conjugate for Multivalent Paclitaxel and Gemcitabine Co-Delivery. Biomaterials science, 9(14), 5000-5010.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!